Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

NCT05222932 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: TILT-123
DRUG: Avelumab

Sponsor

TILT Biotherapeutics Ltd.